UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 573.0	$ 681.8
Short-term investments	96.8	50.0
Accounts receivable, net	372.1	335.3
Inventories	732.8	692.3
Assets held for sale	4.5	0.0
Other current assets	210.1	165.6
Total current assets	1,989.3	1,925.0
Property, plant and equipment, net	389.4	395.5
Goodwill	324.2	320.4
Intangible assets, net	217.7	229.1
Assets held for sale	0.4	0.0
Other long-term assets	206.7	179.0
Total assets	3,127.7	3,049.0
Current liabilities:
Current portion of long-term debt	109.5	2.2
Accounts payable	141.1	134.6
Customer advances	178.3	189.2
Other current liabilities	492.3	465.9
Total current liabilities	921.2	791.9
Long-term debt	717.5	842.3
Other long-term liabilities	399.1	440.5
Commitments and contingencies (Note 14)
Redeemable noncontrolling interest	0.3	0.0
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 174,835,498 and 174,045,610 shares issued and 151,690,664 and 151,987,081 shares outstanding at September 30, 2021 and December 31, 2020, respectively	1.7	1.7
Treasury stock, at cost, 23,144,834 and 22,058,529 shares at September 30, 2021 and December 31, 2020, respectively	(738.1)	(667.0)
Accumulated other comprehensive income (loss)	(10.7)	3.7
Other shareholders' equity	1,822.7	1,622.8
Total shareholders' equity attributable to Bruker Corporation	1,075.6	961.2
Noncontrolling interest in consolidated subsidiaries	14.0	13.1
Total shareholders' equity	1,089.6	974.3
Total liabilities, redeemable noncontrolling interest and shareholders' equity	$ 3,127.7	$ 3,049.0